Actions of a novel water-soluble benzodiazepine-receptor agonist JM-1232(−) on synaptic transmission in adult rat spinal substantia gelatinosa neurons

Uemura, Shiro; Fujita, Teizo; Saito, Yoshiro; Kumamoto, Eiichi

doi:10.1016/j.bbrc.2012.01.080

Cited by 22 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCs are the most common type of seeded cells, and have been shown to improve nerve regeneration. Similarly, induced pluripotent stem cells, which are derived from skin fibroblasts, have also been shown to improve nerve recovery repairing sciatic nerve defects in rats [53,56]. Neural stem cells, mesenchymal stem cells (MSCs), and induced pluripotent stem cells are optimal candidates as they can differentiate into any neural cell type.…”

Section: Overview Of Tissue Engineering Of a Nerve Graftmentioning

confidence: 99%

Bioprinting of Nerve

Owens

Marga

Forgács

2015

Essentials of 3D Biofabrication and Translation

View full text Add to dashboard Cite

Section: Overview Of Tissue Engineering Of a Nerve Graftmentioning

confidence: 99%

Bioprinting of Nerve

Owens

Marga

Forgács

2015

Essentials of 3D Biofabrication and Translation

View full text Add to dashboard Cite

“…[30] Although structurally not a benzodiazepine, JM-1232 (-) allosterically modulates GABA A receptor in a manner that seems to be identical to benzodiazepines and its activity can be inhibited by flumazenil, strongly suggesting that it binds to the same site on the GABA A receptor as classic benzodiazepines. [595838] In addition to its sedative–hypnotic actions, JM-1232 (-) has been shown in animals to possess antinociceptive properties and have a therapeutic index of >38.5, which indicates a safety margin that is greater than propofol, midazolam, thiopental, and even etomidate. [30388]…”

Section: Rational Designmentioning

confidence: 99%

Anesthetic drug development: Novel drugs and new approaches

Chitilian

Eckenhoff²,

Raines³

2013

Surg Neurol Int

View full text Add to dashboard Cite

The ideal sedative–hypnotic drug would be a rapidly titratable intravenous agent with a high therapeutic index and minimal side effects. The current efforts to develop such agents are primarily focused on modifying the structures of existing drugs to improve their pharmacodynamic and pharmacokinetic properties. Drugs currently under development using this rational design approach include analogues of midazolam, propofol, and etomidate, such as remimazolam, PF0713, and cyclopropyl methoxycarbonyl-etomidate (MOC-etomidate), respectively. An alternative approach involves the rapid screening of large libraries of molecules for activity in structural or phenotypic assays that approximate anesthetic and target receptor interactions. Such high-throughput screening offers the potential for identifying completely novel classes of drugs. Anesthetic drug development is experiencing a resurgence of interest because there are new demands on our clinical practice that can be met, at least in part, with better agents. The goal of this review is to provide the reader with a glimpse of the novel anesthetic drugs and new developmental approaches that lie on the horizon.

show abstract

“…This may be a result of an increase in the spontaneous release of gamma-aminobutyric acid (GABA) and glycine from nerve terminals in the substantia gelatinosa, decreasing excitability of the neurons [22]. This may be a result of an increase in the spontaneous release of gamma-aminobutyric acid (GABA) and glycine from nerve terminals in the substantia gelatinosa, decreasing excitability of the neurons [22].…”

Section: Etomidate Analoguesmentioning

confidence: 99%